首页|布地奈德福莫特罗联合异丙托溴铵对COPD急性加重期患者肺功能、症状消失时间的影响

布地奈德福莫特罗联合异丙托溴铵对COPD急性加重期患者肺功能、症状消失时间的影响

扫码查看
目的 探究布地奈德福莫特罗联合异丙托溴铵对慢性阻塞性肺疾病(COPD)急性加重期患者的影响.方法 选取 2022 年 3 月—2023 年 6 月烟台市莱阳中心医院呼吸与危重症医学科收治的 90 例COPD急性加重期患者为研究对象,按随机数字表法将其分为对照组和观察组,各 45 例,对照组采用异丙托溴铵治疗,观察组在对照组的基础上加用布地奈德福莫特罗治疗,两组共治疗 7d.对比两组的肺功能、症状消失时间、炎症反应、不良反应发生情况.结果 观察组喘憋、气促、哮鸣音、咳嗽消失时间均短于对照组,组间差异有统计学意义(P<0.05);治疗后,观察组用力肺活量(FVC)、第 1 秒用力呼气容积(FEV1)、FEV1/FVC水平均大于对照组,组间差异有统计学意义(P<0.05);观察组C-反应蛋白、白细胞介素-6、肿瘤坏死因子-α水平均低于对照组,组间差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论 布地奈德福莫特罗与异丙托溴铵治疗COPD急性加重期患者能够加快症状、炎症反应减轻或消失,改善肺功能,且不良反应少.
Effects of Budesonide Formoterol Combined with Ipratropium Bromide on Pulmonary Function and Symptom Resolution Time in Patients with Acute Exacerbation of COPD
Objective To investigate the effects of budesonide formoterol combined with ipratropium bromide on patients with acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods A total of 90 patients with acute exacerbation of COPD admitted to the Respiratory and Critical Care Medicine Department of Yantai Laiyang Central Hospital from March 2022 to June 2023 were selected as the study objects and were divided into a control group and an observation group according to random number table method,with 45 cases in each group.The control group was treated with ipratropium bromide,the observation group was treated with budesonide formoterol on the basis of the control group,and the two groups were treated for 7 days.Lung function,time of symptom disappearance,inflammation and adverse reactions were compared between the two groups.Results The disappearance time of dyspnea,shortness of breath,wheezing sound and cough in observation group was shorter than that in control group,and the differences between groups werestatistically significant(P<0.05).After treatment,the levels of forced vital capacity(FVC),forced expiratory volume in one second(FEV1)and FEV1/FVC in the observation group were greater than those in the control group,and the differences between groups were statistically significant(P<0.05).The levels of C-reactive protein,interleukin-6,tumor necrosis factor-α in observation group were lower than those in control group,and the differences between groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Budesonide formoterol and ipratropium in the treatment of acute exacerbation of COPD can accelerate symptoms,reduce or disappear inflammation,improve lung function,and reduce adverse reactions.

Chronic obstructive pulmonary diseaseAcute exacerbation stageBudesonide formoterolIpratropium bromideLung function

吕铮铮、王丽娟

展开 >

烟台市莱阳中心医院呼吸与危重症医学科,山东莱阳 265200

慢性阻塞性肺疾病 急性加重期 布地奈德福莫特罗 异丙托溴铵 肺功能

2024

反射疗法与康复医学

反射疗法与康复医学

ISSN:
年,卷(期):2024.5(9)